Drug Approval | September 16, 2025
Rona submits IND for GalNAc-conjugated siRNA targeting obesity
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Subscribe To Our Newsletter & Stay Updated
